On November 12, Genmab A/S fell 4.09% in Regular Trading, trading at $51.62/share, with Turnover of $66.8827 million.
The move followed a pullback after earlier catalysts had already driven a sharp re-rating, with trading momentum cooling around the company’s recent earnings beat and positive Petosemtamab phase 3 update.
Genmab A/S previously reported third-quarter EPS of $5.51, well above the $3.59 consensus estimate, while sales were $1.187 billion versus $1.194 billion expected, and it maintained full-year guidance. Separately, Petosemtamab plus pembrolizumab met both primary endpoints in the phase 3 LiGeR-HN1 study, reducing the risk of death by 50% in certain first-line head and neck cancer patients. Recent weakness appears tied to fading event-driven momentum after those gains were already reflected in the share price.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)